Neena M. Patil
Known title: EVP & Chief Legal OfficerCIK: 0001783908
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Teleflex Shares Lag Peers Amid Q2 Earnings and Value Debate. Teleflex (TFX) recently released its Q2 2026 earnings call transcript, which has fueled ongoing discussions about its valuation relative to peers like Sonovion. While some analysts highlight its status as a value stock, others have flagged concerns within the broader healthcare sector. The stock is currently trading near its 52-week low, reflecting a cautious market sentiment despite an average analyst target that remains significantly higher than the current price.
Transaction History
| JAZZ | ▼ Sell | Open Market | 1,200 | $289K | 9/10/2026 | View on chart |
| JAZZ | ▼ Sell | Tax Withholding | 2,678 | $637K | 6/30/2026 | View on chart |
| JAZZ | ▼ Sell | Open Market | 1,200 | $278K | 6/10/2026 | View on chart |
| JAZZ | ▼ Sell | Open Market | 1,192 | $282K | 5/28/2026 | View on chart |
| TFX | ▲ Buy | Grant | 1,090 | $0 | 5/15/2026 | View on chart |
| JAZZ | ▼ Sell | Tax Withholding | 5,000 | $943K | 3/5/2026 | View on chart |
| JAZZ | ▼ Sell | Open Market | 2,916 | $553K | 2/26/2026 | View on chart |
| JAZZ | ▼ Sell | Open Market | 875 | $168K | 2/26/2026 | View on chart |
| JAZZ | ▲ Buy | Grant | 10,079 | $0 | 2/26/2026 | View on chart |
| JAZZ | ▲ Buy | Option Exercise | 2,916 | $400K | 2/26/2026 | View on chart |
| JAZZ | ▼ Sell | Open Market | 16,602 | $3.2M | 2/26/2026 | View on chart |
| JAZZ | ▼ Sell | Open Market | 15,555 | $3.0M | 2/26/2026 | View on chart |
| JAZZ | ▲ Buy | Option Exercise | 875 | $99K | 2/26/2026 | View on chart |
| JAZZ | ▲ Buy | Option Exercise | 27,084 | $3.7M | 2/26/2026 | View on chart |
| JAZZ | ▼ Sell | Open Market | 11,529 | $2.2M | 2/26/2026 | View on chart |
| JAZZ | ▼ Sell | Open Market | 3,523 | $682K | 2/26/2026 | View on chart |
| JAZZ | ▼ Sell | Open Market | 1,061 | $202K | 2/26/2026 | View on chart |
| JAZZ | ▼ Sell | Open Market | 549 | $105K | 2/26/2026 | View on chart |
| JAZZ | ▼ Sell | Open Market | 1,784 | $342K | 2/26/2026 | View on chart |
| JAZZ | ▼ Sell | Open Market | 1,009 | $195K | 2/26/2026 | View on chart |
| JAZZ | ▲ Buy | Option Exercise | 20,125 | $2.3M | 2/26/2026 | View on chart |
| JAZZ | ▼ Sell | Open Market | 197 | $38K | 2/26/2026 | View on chart |
| JAZZ | ▲ Buy | Grant | 8,852 | $0 | 1/16/2026 | View on chart |
| JAZZ | ▼ Sell | Other | 3,275 | $561K | 1/16/2026 | View on chart |
| TFX | ▲ Buy | Grant | 1,051 | $0 | 5/9/2025 | View on chart |
| JAZZ | ▼ Sell | Other | 4,088 | $568K | 3/5/2025 | View on chart |
| JAZZ | ▼ Sell | Open Market | 3,800 | $551K | 2/27/2025 | View on chart |
| JAZZ | ▲ Buy | Grant | 5,778 | $0 | 2/27/2025 | View on chart |
| JAZZ | ▲ Buy | Grant | 12,518 | $0 | 2/27/2025 | View on chart |
| JAZZ | ▲ Buy | Grant | 5,864 | $0 | 1/17/2025 | View on chart |
| JAZZ | ▼ Sell | Tax Withholding | 1,905 | $234K | 1/17/2025 | View on chart |
| JAZZ | ▼ Sell | Open Market | 3,700 | $457K | 11/8/2024 | View on chart |
| TFX | ▲ Buy | Grant | 649 | $0 | 5/7/2024 | View on chart |
| JAZZ | ▼ Sell | Open Market | 5,000 | $548K | 5/3/2024 | View on chart |
| JAZZ | ▼ Sell | Tax Withholding | 3,432 | $403K | 3/5/2024 | View on chart |
| JAZZ | ▲ Buy | Grant | 12,348 | $0 | 3/1/2024 | View on chart |
| JAZZ | ▼ Sell | Tax Withholding | 1,656 | $197K | 1/17/2024 | View on chart |
| JAZZ | ▲ Buy | Grant | 5,087 | $0 | 1/17/2024 | View on chart |
| JAZZ | ▼ Sell | Open Market | 1,500 | $216K | 9/1/2023 | View on chart |
| JAZZ | ▼ Sell | Open Market | 750 | $105K | 8/15/2023 | View on chart |
| JAZZ | ▼ Sell | Other | 1,390 | $183K | 8/7/2023 | View on chart |
| JAZZ | ▼ Sell | Open Market | 1,526 | $195K | 6/1/2023 | View on chart |
| JAZZ | ▼ Sell | Open Market | 74 | $9K | 6/1/2023 | View on chart |
| TFX | ▲ Buy | Grant | 527 | $0 | 5/9/2023 | View on chart |
| JAZZ | ▼ Sell | Tax Withholding | 1,923 | $275K | 3/5/2023 | View on chart |
| JAZZ | ▲ Buy | Grant | 9,419 | $0 | 3/3/2023 | View on chart |
| JAZZ | ▼ Sell | Open Market | 3,510 | $500K | 11/16/2022 | View on chart |
| JAZZ | ▼ Sell | Tax Withholding | 1,321 | $203K | 8/5/2022 | View on chart |
| JAZZ | ▼ Sell | Open Market | 1,000 | $152K | 6/6/2022 | View on chart |
| JAZZ | ▼ Sell | Gift | 161 | $0 | 5/10/2022 | View on chart |
| JAZZ | ▼ Sell | Open Market | 296 | $46K | 5/6/2022 | View on chart |
| TFX | ▲ Buy | Grant | 399 | $0 | 5/3/2022 | View on chart |
| JAZZ | ▼ Sell | Tax Withholding | 1,228 | $189K | 3/5/2022 | View on chart |
| JAZZ | ▲ Buy | Grant | 8,886 | $0 | 3/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
JAZZ: Ziihera FDA win and leadership change shift company outlook
Jazz Pharmaceuticals recently received FDA approval for Ziihera and underwent a leadership change, which analysts suggest may alter the investment case. The company is also diversifying its portfolio, changing the narrative around its earnings. While the stock is currently trading near its 52-week low, the average analyst target price remains significantly higher than the current market level.
JAZZ: Ziihera FDA win and leadership change shift company outlook. Jazz Pharmaceuticals recently received FDA approval for Ziihera and underwent a leadership change, which analysts suggest may alter the investment case. The company is also diversifying its portfolio, changing the narrative around its earnings. While the stock is currently trading near its 52-week low, the average analyst target price remains significantly higher than the current market level.